Literature DB >> 15053250

Erectile dysfunction: symptom or disease?

C Foresta1, N Caretta, A Aversa, C Bettocchi, G Corona, S Mariani, M Rossato.   

Abstract

Erectile dysfunction (ED) has been defined by the National Institute of Health (NIH) as the inability to achieve and/or to maintain an erection for a sufficiently long period of time so as to permit satisfactory sexual intercourse. ED affects millions of men throughout the world and could have a negative influence on the individual's well-being as well as on the quality of life of affected subjects. Discordant data have been reported on ED epidemiology with prevalence ranging from 12% to 52%, probably depending on the different criteria utilized in the different studies for patient selection. ED is a symptom, sometimes the first, of different pathological conditions. In 15.7% of 45-yr-old patients with vascular ED a dynamic ergometric test has shown electrocardiographic alterations in the absence of any cardiac symptom. In 15% of the patients with ED, high fasting glucose plasma levels are discovered for the first time and in patients with ED and normal fasting glucose plasma levels the prevalence of undiagnosed diabetes mellitus is 12.1% after an oral glucose tolerance test (OGTT). The different risk factors are often additive in the possible development of systemic vasculopathy, neuropathy and ED. ED, underestimated in clinical practice due to archaic prejudice which hinders the patient in spontaneously revealing the problem and the physicians in investigating it, can mark the point where evaluation and prevention of important diseases (such as diabetes, arterial hypertension, atherosclerosis) hitherto unknown by the patients, can begin. The physicians' cultural baggage must include the ability to identify the pathology that can determine ED and the ability to program a specific diagnostic workup. In this paper the different specialists involved in ED diagnosis agreed that a clinical approach which allows the identification of systemic pathologies contributing to the development of ED constitutes an improvement in disease prognosis and may either induce a spontaneous reduction of ED or facilitate its specific treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15053250     DOI: 10.1007/BF03350917

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  106 in total

1.  Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction.

Authors:  K Sairam; E Kulinskaya; G B Boustead; D C Hanbury; T A McNicholas
Journal:  BJU Int       Date:  2001-07       Impact factor: 5.588

2.  Some side-effects of alpha-methyldopa.

Authors:  V K Pillay
Journal:  S Afr Med J       Date:  1976-04-10

3.  Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort.

Authors:  C A Derby; M M Barbour; A L Hume; J B McKinlay
Journal:  Pharmacotherapy       Date:  2001-06       Impact factor: 4.705

4.  Undiagnosed NIDDM: clinical and public health issues.

Authors:  M I Harris
Journal:  Diabetes Care       Date:  1993-04       Impact factor: 19.112

5.  Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction.

Authors:  B Davis-Joseph; L Tiefer; A Melman
Journal:  Urology       Date:  1995-03       Impact factor: 2.649

Review 6.  Diagnosis and treatment of erectile dysfunction.

Authors:  L A Levine
Journal:  Am J Med       Date:  2000-12-18       Impact factor: 4.965

7.  Frequency and determinants of erectile dysfunction in Italy.

Authors:  F Parazzini; F Menchini Fabris; A Bortolotti; A Calabrò; L Chatenoud; E Colli; M Landoni; M Lavezzari; P Turchi; A Sessa; V Mirone
Journal:  Eur Urol       Date:  2000-01       Impact factor: 20.096

8.  Impotence in medical clinic outpatients.

Authors:  M F Slag; J E Morley; M K Elson; D L Trence; C J Nelson; A E Nelson; W B Kinlaw; H S Beyer; F Q Nuttall; R B Shafer
Journal:  JAMA       Date:  1983-04-01       Impact factor: 56.272

9.  Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction.

Authors:  Antonio Aversa; Andrea M Isidori; Giovanni Spera; Andrea Lenzi; Andrea Fabbri
Journal:  Clin Endocrinol (Oxf)       Date:  2003-05       Impact factor: 3.478

Review 10.  Sympathetic skin response.

Authors:  J A Gutrecht
Journal:  J Clin Neurophysiol       Date:  1994-09       Impact factor: 2.177

View more
  3 in total

1.  Cardiovascular risk engines can help in selecting patients to be evaluated by dynamic penile color doppler ultrasound.

Authors:  G Corona; E Mannucci; A D Fisher; F Lotti; E Bandini; L Vignozzi; G Balercia; F Paggi; L Petrone; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2008-12       Impact factor: 4.256

Review 2.  Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition.

Authors:  A Aversa; M Pili; A Fabbri; E Spera; G Spera
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

3.  Prevalence and associated factors of undiagnosed glycaemic disorders in men with erectile dysfunction attending a primary care clinic.

Authors:  Yoke Lan Ng; Soo Huat Teoh; A Rashid Mohd Radzniwan; Mohd Hashim Syahnaz
Journal:  J Taibah Univ Med Sci       Date:  2019-01-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.